Literature DB >> 3348106

Rhabdomyolysis and acute renal failure following an overdose of doxepine and nitrazepam.

A D Højgaard1, P T Andersen, J Møller-Petersen.   

Abstract

A 50-year-old woman developed rhabdomyolysis and myoglobinuric renal impairment after an oral dose of 250 mg nitrazepam and 1,250 mg doxepin. Serum creatinine increased from 70 mumol/l to 472 mumol/l in two days. Serum creatine phosphokinase reached a maximal level of 391 mu kat/l (reference range less than 2.5 mu kat/l) on the third day and serum myoglobin was maximally 910 nmol/l (reference range less than 4.5 nmol/l) on the fourth day after the overdose. Passive and active movements of the knees and ankles became increasingly restricted, but the patient felt no muscle pain. Diuresis decreased to 20-22 ml/hour in spite of repetitive doses of furosemide, but was enforced to greater than 100 ml/hour by vigorous infusion of saline. Haemodialysis was avoided on this regimen. It is suggested that in patients intoxicated with nitrazepam and/or doxepin, rhabdomyolysis should be suspected when a rapidly increasing serum concentration of creatinine is found, even in the absence of muscle pain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348106     DOI: 10.1111/j.0954-6820.1988.tb15768.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  Misuse of temazepam.

Authors:  M M Hudson; M Edmonds; P J Watkins
Journal:  BMJ       Date:  1991-10-19

Review 2.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

3.  Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice.

Authors:  Geng-Ruei Chang; Po-Hsun Hou; Wei-Cheng Yang; Chao-Min Wang; Pei-Shan Fan; Huei-Jyuan Liao; To-Pang Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.